FORM 4

## **UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

<b>STATEMENT</b>	OF CHANGES	IN BENEFICIAL	<b>OWNERSHIP</b>

	OMB APP	IB APPROVAL						
	OMB Number:	3235-0287						
	Estimated average burden							
- 1	hours per response.	0.5						

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>Jene Jill M.</u>				2. Issuer Name and Ticker or Trading Symbol PDL BIOPHARMA, INC. [ PDLI ]							eck all application	able)	Person(s) to Issu 10% Ov	vner	
(Last) (First) (Middle) 932 SOUTHWOOD BLVD.				3. Date of Earliest Transaction (Month/Day/Year) 03/28/2019							below)			Бреспу	
(Street) INCLINI VILLAG	N	V	89451	4.	4. If Amendment, Date of Original Filed (Month/Day/Year)				6. I Lin	e) <mark>X</mark> Form fil Form fil	lividual or Joint/Group Filing (Check Applicable  Form filed by One Reporting Person  Form filed by More than One Reporting Person				
(City)	(S	tate)	(Zip)												
	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned														
1. Title of Security (Instr. 3)  2. Trans. Date (Month/I			•	action 2A. Deemed Execution Date, if any (Month/Day/Year)		Code (Instr.		ed (A) or str. 3, 4 and	5. Amour Securities Beneficia Owned For	s Form lly (D) o ollowing (I) (In	Form: Direct D) or Indirect I) (Instr. 4)	7. Nature of ndirect Beneficial Ownership			
						Code V	Amount	(A) o (D)	r Price	Transacti (Instr. 3 a	on(s)		(Instr. 4)		
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)															
1. Title of Derivative Security (Instr. 3)	or Exercise (Month/Day/Year) if any		Execution Date,	Code (Instr.		Derivative		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s)	Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		(Instr. 4)	1(5)	
Stock Option (right to buy)	\$3.72	03/28/2019		A		377,358		(1)	03/28/2029	Common stock	377,358	\$0	377,358	D	

## Explanation of Responses:

1. The stock options will vest as follows: (a) 25% of the shares subject to the option shall vest on the one year anniversary of January 1, 2019 and (b) 75% of the shares subject to the option shall vest on a monthly basis pro rata over the thirty-six (36) months following the one year anniversary of January 1, 2019, provided that the recipient's continuous service has not terminated prior to the applicable vesting date, subject to earlier vesting upon a change in control and certain qualifying terminations of employment provided in the severance agreement between the issuer and the recipient.

## Remarks:

/s/ Nathan N. Kryszak, Attorney-In-Fact for Jill Jene

03/29/2019

\*\* Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- $^{\star}$  If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.